Purchase Order 75N93018P00690
- Not listed
- This federal contract award was made by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a for-profit biotechnology company based in Piscataway, New Jersey. The $10,470.54 firm fixed price purchase order was awarded on November 1, 2019 with a completion date of October 29, 2020. Genscript provides a wide range of products and services to federal agencies in the areas of biomedical research...
- This federal contract award to Genscript USA Inc., a biotechnology company based in New Jersey, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $4,196.16 firm fixed-price purchase order is for gene synthesis services. Genscript, a for-profit organization, has a history of providing a wide range of molecular biology products and services to...
- This $4,448.22 firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for custom protein and DNA synthesis services to support biomedical research and public health initiatives. Genscript specializes in providing a range of molecular biology products and services, including gene...
- This firm-fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, to Genscript USA Inc., a for-profit biotechnology company. The $118,272.00 contract is for the provision of customized antibody expressions and plasmid preparations to support biomedical research and public health initiatives. The award has a completion date of November 1, 2020 and does not include a set-aside designation. Genscript...
- This is a $164,700 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support critical research initiatives, with a period of performance through June 15, 2026. While the contract does not have a set-aside...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $3,800.00, is for custom monoclonal antibody production services to support NIAID's biomedical research and public health initiatives. This contract does not have a set-aside designation. Genscript...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm fixed price purchase order to GenScript USA Inc., a for-profit biotechnology company, to provide custom monoclonal antibody production services. The $13,758.30 contract has an October 16, 2019 completion date and was awarded on August 14, 2019. GenScript, based in Piscataway, New Jersey, specializes in gene synthesis, protein production, and other...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Genscript USA Inc., a for-profit biotechnology company, to provide antibody efficiency testing services. The $119,213.05 contract has a completion date of September 30, 2022 and does not utilize a set-aside designation. Genscript previously held a $1.5 million blanket purchase agreement with the U.S. Department of...
- This is a $97,722.00 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's research initiatives, with a completion date of September 19, 2025. This contract is not designated as a set-aside....
- This is a $8,073.05 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the synthesis of a specific gene, HHSN272201200153P. Genscript, which is not a small business set-aside, has received numerous previous contracts from HHS agencies like the National Institutes of Health, Centers for...
This $8,435.16 firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services' National Institutes of Health, to Genscript USA Inc., a for-profit biotechnology company located in Piscataway, New Jersey. The contract is for antibody production services, with a completion date of June 15, 2018. Genscript specializes in providing a range of biomedical research and public health products and services to federal agencies, including gene synthesis, gene editing, and custom protein/antibody production. The company has received numerous prime and subcontract awards from agencies like the NIH, CDC, FDA, and USDA to support the rapid development of research materials for emerging infectious disease threats. While most of Genscript's federal contracts do not have set-aside designations, the company has received some small business set-aside awards from the NIH and USDA. Genscript currently holds a $1.5 million blanket purchase agreement from the USDA's Animal and Plant Health Inspection Service to provide SARS-CoV-2 surrogate virus neutralization test kits and associated reagents.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.4k | 5/10/18 |